Replies to post #125935 on Biotech Values

[DewDiligence]

Did your list mostly cut off due to scale/resources? Any of the next tier or other foreign firms have a compelling "pro" rationale?

Yes on both counts—some of the second-tier drug/biotech companies could conceivably be FoB partners, but I don’t think any of them individually is likely enough to try to handicap such deals.